HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Another Notice For Comments On Kratom: Cue Second Wave Of Support For Botanical In US?

Executive Summary

FDA states in Federal Register notice that WHO has requested information on whether kratom – mitragynine, 7-hydroxymitragynine – should be added to the United Nations’ schedule of controlled substances.

You may also be interested in...

US Kratom Industry Chafes At FDA’s Short Leash On Science Showing Botanical’s Safety, Benefits

American Kratom Association didn’t convince court to order FDA to extend to deadline for comments responding to World Health Organization’s question on whether kratom should be deemed controlled substances under UN schedule. Short comment period is “latest in what we think is a very hostile action” by FDA about kratom, says AKA executive Mac Haddow.

FDA’s Proposed IND Study For ‘Abuse Potential’ Could Close US Kratom Supplement Market

RFP states FDA "previously warned consumers about the use of Kratom (Mitragyna speciosa)” and although botanical’s “use is prevalent, to date, clinical evaluations of abuse potential have not been performed.”

With Seizure in Florida, FDA Targets Kratom As Unsafe For Any Use

Kratom industry says complaint filed in Florida federal court shows FDA’s switching reasons to stop all sales of the ingredient in the US.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts